Molbio Diagnostics Limited has intimated the stock exchanges about an upcoming Board of Directors meeting scheduled for Saturday, September 05, 2026. The meeting will be conducted pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The primary agenda items for the board meeting include:
- Consideration and approval of the Unaudited Standalone Financial Results for the quarter ended June 30, 2026
- Consideration and approval of the Unaudited Consolidated Financial Results for the quarter ended June 30, 2026
- Consideration of any other matters with the permission of the Chair
The company confirms that the trading window for dealing in shares of the company remains closed, as previously communicated via letter dated August 20, 2026. The trading window closure period began on August 21, 2026 and will continue until 48 hours after the approval of the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
This intimation has been made available on the company's website at www.molbiodiagnostics.com in compliance with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The communication was digitally signed by Darshan Raghunath Karekar, Company Secretary & Compliance Officer (Membership Number: F13569), from Verna, Goa.